The novel small molecule CBL0137 (curaxin) exhibits antileukemic activity

Curaxin CBL0137 is a new promising antitumor drug, which was selected as NfkB-signaling inhibitor and p53 activator in different cancer cell lines. To investigate whether Curaxin may be applied for acute leukemia therapy, we used three models: human leukemia cell lines, blood samples of leukemia patients and murine leukemia models in vivo. CBL0137 decreased leukemic cells viability, reduced expression of WNT target genes in vitro and ex vivo and demonstrated antileukemic activity in vivo.

Authors
Fetisov T.I.1 , Kuzin K.A.1 , Zenkov R.G.1 , Safina A. 4 , Lesovaya E.A.1 , Trukhanova L.S.1 , Antoshina E.E.1 , Gorkova T.G.1 , Gurova K. 4 , Yakubovskaya M.G.1 , Kirsanov K.I. 1
Conference proceedings
The 22nd International Charles Heidelberger Symposium on Cancer Research
Publisher
Национальный исследовательский Томский государственный университет
Language
English
Pages
29-30
Status
Published
Year
2018
Organizations
  • 1 Blokhin NMRCO, Department of Chemical Carcinogenesis
  • 2 Roswell Park Cancer Institute, Department of Cell Stress Biology
  • 3 Ryazan State Medical University
  • 4 RUDN University
Keywords
curaxin; Wnt signaling pathway; myeloid; Lymphoid; leukemia
Date of creation
07.11.2019
Date of change
07.11.2019
Short link
https://repository.rudn.ru/en/records/article/record/53185/
Share

Other records

THE INFLUENCE OF ORGANIC SOLVENTS ON THE EPIGENETIC REGULATION OF GENE EXPRESSION

Article
Maximova V.P., Lizogub O.P., Fedorov D.A., Zhidkova E.M., Lesovaya E.A., Kholodova A.V., Belitsky G.A., Yakubovskaya M.G., Kirsanov K.I.
The 22nd International Charles Heidelberger Symposium on Cancer Research. Национальный исследовательский Томский государственный университет. 2018. P. 68-70